Mackenzie Financial Corp Has $540,000 Position in Accuray Incorporated (NASDAQ:ARAY)

Mackenzie Financial Corp grew its position in Accuray Incorporated (NASDAQ:ARAY - Free Report) by 1,123.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 272,846 shares of the medical equipment provider's stock after purchasing an additional 250,539 shares during the quarter. Mackenzie Financial Corp owned approximately 0.27% of Accuray worth $540,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Gabelli Funds LLC raised its position in shares of Accuray by 12.5% in the fourth quarter. Gabelli Funds LLC now owns 45,000 shares of the medical equipment provider's stock valued at $89,000 after purchasing an additional 5,000 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Accuray by 2.0% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 283,280 shares of the medical equipment provider's stock valued at $561,000 after purchasing an additional 5,421 shares during the period. Geode Capital Management LLC raised its position in shares of Accuray by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 2,186,154 shares of the medical equipment provider's stock valued at $4,329,000 after purchasing an additional 6,758 shares during the period. Northern Trust Corp raised its position in shares of Accuray by 0.9% in the fourth quarter. Northern Trust Corp now owns 809,665 shares of the medical equipment provider's stock valued at $1,603,000 after purchasing an additional 7,399 shares during the period. Finally, ProShare Advisors LLC raised its position in shares of Accuray by 50.7% in the fourth quarter. ProShare Advisors LLC now owns 27,308 shares of the medical equipment provider's stock valued at $54,000 after purchasing an additional 9,187 shares during the period. Institutional investors own 64.08% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Accuray from a "hold" rating to a "buy" rating in a research report on Friday, May 30th.

Accuray Stock Performance

Shares of NASDAQ:ARAY traded down $0.23 during trading on Friday, reaching $1.29. The stock had a trading volume of 7,525,616 shares, compared to its average volume of 741,693. Accuray Incorporated has a 52 week low of $1.15 and a 52 week high of $2.95. The firm has a market capitalization of $132.89 million, a price-to-earnings ratio of -25.80 and a beta of 1.30. The company has a quick ratio of 0.88, a current ratio of 1.62 and a debt-to-equity ratio of 3.51. The stock has a fifty day simple moving average of $1.54 and a two-hundred day simple moving average of $1.88.

Accuray (NASDAQ:ARAY - Get Free Report) last announced its earnings results on Wednesday, April 30th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.04. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. The business had revenue of $113.24 million for the quarter, compared to analyst estimates of $101.53 million. As a group, analysts anticipate that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.